Angiotensin II receptor blocker (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Angiotensin II receptor blocker" in English language version.

refsWebsite

Global rank English rank

63nih.gov

4^th place

45doi.org

2^nd place

15semanticscholar.org

11^th place

8^th place

11web.archive.org

1^st place

9fda.gov

447^th place

338^th place

5worldcat.org

5^th place

3europa.eu

68^th place

117^th place

2edqm.eu

low place

1drugs.com

399^th place

333^rd place

1bloodpressureuk.org

low place

1medscape.com

719^th place

636^th place

1uptodate.com

3,771^st place

2,605^th place

1harvard.edu

18^th place

17^th place

1wsj.com

79^th place

65^th place

1pharmacytimes.com

low place

1drugbank.ca

4,294^th place

6,357^th place

1proquest.com

206^th place

124^th place

1lww.com

2,769^th place

3,314^th place

1tga.gov.au

3,984^th place

2,622^nd place

1globo.com

62^nd place

304^th place

1chemistryworld.com

low place

9,688^th place

1swissmedic.ch

low place

1quickcompany.in

low place

bloodpressureuk.org

"Blood Pressure : Angiotensin receptor blockers (ARBs)". blood pressure medication. Archived from the original on 2012-12-14. Retrieved 2020-03-21.

chemistryworld.com

Chapman, Kit (29 June 2021). "Sartan contaminant recall hits generics manufacturers". Chemistry World. Retrieved 26 June 2022.

doi.org

Mirabito Colafella, Katrina M.; Uijl, Estrellita; Jan Danser, A.H. (2019). "Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches". Encyclopedia of Endocrine Diseases. Elsevier. pp. 523–530. doi:10.1016/b978-0-12-801238-3.65341-2. ISBN 978-0-12-812200-6. S2CID 86384280.
Hu, Yiyun (2023). "Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis". Journal of Clinical Hypertension (Greenwich, Conn.). 25 (8): 661–688. doi:10.1111/jch.14695. PMC 10423763. PMID 37417783.
Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P (November 1998). "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients". British Journal of Clinical Pharmacology. 46 (5): 467–71. doi:10.1046/j.1365-2125.1998.00811.x. PMC 1873694. PMID 9833600.
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (January 2003). "Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial". JAMA. 289 (1): 65–9. doi:10.1001/jama.289.1.65. PMID 12503978. S2CID 35939042.
Cernes R, Mashavi M, Zimlichman R (2011). "Differential clinical profile of candesartan compared to other angiotensin receptor blockers". Vascular Health and Risk Management. 7: 749–59. doi:10.2147/VHRM.S22591. PMC 3253768. PMID 22241949.
Gales BJ, Bailey EK, Reed AN, Gales MA (February 2010). "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines". The Annals of Pharmacotherapy. 44 (2): 360–6. doi:10.1345/aph.1M312. PMID 20086184. S2CID 207263658.
Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E (April 1998). "Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators". American Journal of Hypertension. 11 (4 Pt 1): 445–53. doi:10.1016/S0895-7061(97)00491-3. PMID 9607383.
Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B (January 2006). "Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population". Journal of Human Hypertension. 20 (1): 45–50. doi:10.1038/sj.jhh.1001941. PMID 16281062. S2CID 25534200.
Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M (2005). "Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia". Current Pharmaceutical Design. 11 (32): 4161–75. doi:10.2174/138161205774913309. PMID 16375738.
Pavel J, Benicky J, Murakami Y, Sanchez-Lemus E, Saavedra JM (December 2008). "Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo". Annals of the New York Academy of Sciences. 1148 (1): 360–6. Bibcode:2008NYASA1148..360P. doi:10.1196/annals.1410.006. PMC 2659765. PMID 19120129.
Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (January 2010). "Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis". BMJ. 340 (9): b5465. doi:10.1136/bmj.b5465. PMC 2806632. PMID 20068258.
"Potential of antihypertensive drugs for the prevention and treatment of Alzheimer's disease". Expert Review of Neurotherapeutics. 8 (9): 1285–1287. September 2008. doi:10.1586/14737175.8.9.1285.
Fuentes, Blanca (2010). "Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction". Journal of Hypertension. 28 (3): 575–581. doi:10.1097/HJH.0b013e3283350f50. PMID 20090554. S2CID 28972688.
Li EC, Heran BS, Wright JM (August 2014). "Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension". The Cochrane Database of Systematic Reviews. 2014 (8): CD009096. doi:10.1002/14651858.CD009096.pub2. PMC 6486121. PMID 25148386.
Strauss MH, Hall AS (August 2006). "Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox". Circulation. 114 (8): 838–54. doi:10.1161/CIRCULATIONAHA.105.594986. PMID 16923768.
Tsuyuki RT, McDonald MA (August 2006). "Angiotensin receptor blockers do not increase risk of myocardial infarction". Circulation. 114 (8): 855–60. doi:10.1161/CIRCULATIONAHA.105.594978. PMID 16923769.
Levy BI (September 2005). "How to explain the differences between renin angiotensin system modulators". American Journal of Hypertension. 18 (9 Pt 2): 134S – 141S. doi:10.1016/j.amjhyper.2005.05.005. PMID 16125050.
Lévy BI (January 2004). "Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system". Circulation. 109 (1): 8–13. doi:10.1161/01.CIR.0000096609.73772.C5. PMID 14707017.
Reudelhuber TL (December 2005). "The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous". Hypertension. 46 (6): 1261–2. doi:10.1161/01.HYP.0000193498.07087.83. PMID 16286568.
Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (July 2010). "Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials". The Lancet. Oncology. 11 (7): 627–36. doi:10.1016/S1470-2045(10)70106-6. PMC 4070221. PMID 20542468.
Rao GA, Mann JR, Shoaibi A, Pai SG, Bottai M, Sutton SS, et al. (August 2013). "Angiotensin receptor blockers: are they related to lung cancer?". Journal of Hypertension. 31 (8): 1669–75. doi:10.1097/HJH.0b013e3283621ea3. PMC 3879726. PMID 23822929.
Rao GA, Mann JR, Bottai M, Uemura H, Burch JB, Bennett CL, et al. (July 2013). "Angiotensin receptor blockers and risk of prostate cancer among United States veterans". Journal of Clinical Pharmacology. 53 (7): 773–8. doi:10.1002/jcph.98. PMC 3768141. PMID 23686462.
Zhao YT, Li PY, Zhang JQ, Wang L, Yi Z (May 2016). "Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials". Medicine. 95 (18): e3600. doi:10.1097/MD.0000000000003600. PMC 4863811. PMID 27149494.
Tucker, Bryan M.; Perazella, Mark A. (2019). "Medications: 3. What are the major adverse effects on the kidney of ACE inhibitors and ARBs?". Nephrology Secrets. Elsevier. pp. 78–83. doi:10.1016/b978-0-323-47871-7.00019-8. ISBN 978-0-323-47871-7. S2CID 239423283. due to inhibition of angiotensin II production by ACE inhibitors or competitive antagonism of the angiotensin II receptor by ARBs... results in loss of angiotensin II–induced efferent arteriolar tone, leading to a drop in glomerular filtration fraction and GFR. The efferent arteriolal vasodilation reduces intraglomerular hypertension (and pressure-related injury) and maintains perfusion (and oxygenation) of the peritubular capillaries.
Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA (October 1991). "Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis". Annals of Internal Medicine. 115 (7): 513–9. doi:10.7326/0003-4819-115-7-513. PMID 1883120.
Bakris GL, Weir MR (March 2000). "Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?". Archives of Internal Medicine. 160 (5): 685–93. doi:10.1001/archinte.160.5.685. PMID 10724055.
Remuzzi G, Ruggenenti P, Perico N (April 2002). "Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition". Annals of Internal Medicine. 136 (8): 604–15. doi:10.7326/0003-4819-136-8-200204160-00010. PMID 11955029. S2CID 24795760.
Sarafidis PA, Khosla N, Bakris GL (January 2007). "Antihypertensive therapy in the presence of proteinuria". American Journal of Kidney Diseases. 49 (1): 12–26. doi:10.1053/j.ajkd.2006.10.014. PMID 17185142. S2CID 18337587.
Weir MR (October 2002). "Progressive renal and cardiovascular disease: optimal treatment strategies". Kidney International. 62 (4): 1482–92. doi:10.1111/j.1523-1755.2002.kid591.x. PMID 12234333.
Miura, S; Karnik, SS; Saku, K (March 2011). "Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects". Journal of the Renin-Angiotensin-Aldosterone System. 12 (1): 1–7. doi:10.1177/1470320310370852. PMC 3891529. PMID 20603272.
Kjeldsen, Sverre E; Brunner, Hans R; McInnes, Gordon T; Stolt, Pelle (2005). "Valsartan in the treatment of hypertension". Aging Health. 1 (1). Future Medicine Ltd: 27–36. doi:10.2217/1745509x.1.1.27.
Siragy HM (November 2002). "Angiotensin receptor blockers: how important is selectivity?". American Journal of Hypertension. 15 (11): 1006–14. doi:10.1016/s0895-7061(02)02280-x. PMID 12441224.
Fischer, Tracy L.; Pieper, John A.; Graff, Donald W.; Rodgers, Jo E.; Fischer, Jeffrey D.; Parnell, Kimberly J.; Goldstein, Joyce A.; Greenwood, Robert; Patterson, J. Herbert (September 2002). "Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers". Clinical Pharmacology and Therapeutics. 72 (3): 238–246. doi:10.1067/mcp.2002.127945. ISSN 0009-9236. PMID 12235444. S2CID 28606328.
Chi, Yong Ha; Lee, Howard; Paik, Soo Heui; Lee, Joo Han; Yoo, Byoung Wook; Kim, Ji Han; Tan, Hyun Kwang; Kim, Sang Lin (2011-10-01). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects". American Journal of Cardiovascular Drugs. 11 (5): 335–346. doi:10.2165/11593840-000000000-00000. ISSN 1179-187X. PMID 21910510. S2CID 207300735.
Burnier, M.; Brunner, H. R. (2000), "Angiotensin II receptor antagonists", Lancet, 355 (9204): 637–645, doi:10.1016/S0140-6736(99)10365-9, PMID 10696996, S2CID 18835715
Brousil, J. A.; Burke, J. M. (2003), "Olmesartan Medoxomil: An Angiotensin II-Receptor Blocker", Clinical Therapeutics, 25 (4): 1041–1055, doi:10.1016/S0149-2918(03)80066-8, PMID 12809956
Brunner, H. R. (2002), "The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview", Journal of Human Hypertension, 16 (2): 13–16, doi:10.1038/sj.jhh.1001391, PMID 11967728, S2CID 24382600, ProQuest 219966061
Zusman, R. M.; Jullien, V.; Lemetayer, P.; Jarnier, P.; Clementy, J. (1999), "Are There Differences Among Angiotensin Receptor Blockers?", American Journal of Hypertension, 12 (2 Pt 1): 231–235, doi:10.1016/S0895-7061(99)00116-8, PMID 10090354
Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. (March 2009). "Disruption of the Ang II type 1 receptor promotes longevity in mice". The Journal of Clinical Investigation. 119 (3): 524–30. doi:10.1172/JCI36703. PMC 2648681. PMID 19197138.
Cassis P, Conti S, Remuzzi G, Benigni A (January 2010). "Angiotensin receptors as determinants of life span". Pflügers Archiv. 459 (2): 325–32. doi:10.1007/s00424-009-0725-4. PMID 19763608. S2CID 24404339.
Hubbert, Katherine; Clement, Ryan (April 2021). "Losartan: A Novel Treatment for Acute Skeletal Muscle Injury". JBJS Journal of Orthopaedics for Physician Assistants. 9 (2). doi:10.2106/JBJS.JOPA.20.00030. ISSN 2470-1122. S2CID 242846521. Retrieved 14 April 2022.
Salama, Zakaria A.; Sadek, Ahmed; Abdelhady, Ahmed M.; Darweesh, Samar Kamal; Morsy, Shereif Ahmed; Esmat, Gamal (June 2016). "Losartan may inhibit the progression of liver fibrosis in chronic HCV patients". Hepatobiliary Surgery and Nutrition. 5 (3): 249–255. doi:10.21037/hbsn.2016.02.06. ISSN 2304-3881. PMC 4876242. PMID 27275467.
Wang, J; Duan, L; Gao, Y; Zhou, S; Liu, Y; Wei, S; An, S; Liu, J; Tian, L; Wang, S (5 September 2018). "Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice". Molecular and Cellular Endocrinology. 472: 149–158. doi:10.1016/j.mce.2017.12.005. PMID 29233785. S2CID 6615686. Retrieved 14 April 2022.
Naito, T; Ma, LJ; Yang, H; Zuo, Y; Tang, Y; Han, JY; Kon, V; Fogo, AB (March 2010). "Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis". American Journal of Physiology. Renal Physiology. 298 (3): F683-91. doi:10.1152/ajprenal.00503.2009. PMC 2838584. PMID 20042458.
Weinberg MS, Weinberg AJ, Cord RB, Martin H (1 May 2003). "P-609: Regression of dilated aortic roots using supramaximal and usual doses of angiotensin receptor blockers". American Journal of Hypertension. 16 (S1): 259A. doi:10.1016/S0895-7061(03)00782-9. ISSN 0895-7061. In conclusion, we demonstrated regression of DAR using ARBs at moderate and supramaximal doses. Intensive ARB therapy offers a promise to reduce the natural progression of disease in patients with DARs.

drugbank.ca

"Saprisartan". drugbank.ca. Archived from the original on 28 September 2016. Retrieved 1 May 2018.

drugs.com

"List of Angiotensin receptor blockers (angiotensin II inhibitors)". Drugs.com. 2020-02-28. Retrieved 2020-03-21.

edqm.eu

"Risk of presence of mutagenic azido impurities in sartan active substances with a tetrazole ring" (Press release). European Directorate for the Quality of Medicines & HealthCare. 29 April 2021. Retrieved 26 June 2022.
"Risk of the presence of mutagenic azido impurities in losartan active substance" (Press release). European Directorate for the Quality of Medicines & HealthCare. 29 September 2021. Retrieved 26 June 2022.

europa.eu

ema.europa.eu

"Nitrosamine impurities". European Medicines Agency. 23 October 2019. Retrieved 6 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Nitrosamines: EMA aligns recommendations for sartans with those other medicines". European Medicines Agency (EMA) (Press release). 12 November 2020. Retrieved 13 November 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 November 2020.

fda.gov

"Angiotensin FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs – Angiotensin Receptor Blockers (ARBs)". Food and Drug Administration (FDA). 2 June 2011. Archived from the original on 8 December 2011.
"FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)". Food and Drug Administration (FDA). 20 August 2018. Archived from the original on April 28, 2019. Retrieved 17 September 2019.
"Statement on the agency's ongoing efforts to resolve safety issue with ARB medications". Food and Drug Administration (FDA). 28 August 2019. Archived from the original on August 28, 2019. Retrieved 17 September 2019.
"FDA's Assessment of Currently Marketed ARB Drug Products". Food and Drug Administration (FDA). 4 April 2019. Archived from the original on 30 December 2019. Retrieved 17 September 2019.
"Search List of Recalled Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan". Food and Drug Administration (FDA). 28 June 2019. Retrieved 17 September 2019.
"Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP". U.S. Food and Drug Administration. 23 September 2019. Archived from the original on September 24, 2019. Retrieved 24 September 2019.
"General Advice ARB". Food and Drug Administration (FDA). Archived from the original (PDF) on November 12, 2019. Retrieved 17 September 2019. This article incorporates text from this source, which is in the public domain.
"M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk". Food and Drug Administration (FDA). 30 August 2018. Archived from the original (PDF) on August 28, 2019. Retrieved 17 September 2019.
"Control of Nitrosamine Impurities in Human Drugs". U.S. Food and Drug Administration. 24 February 2021. Archived from the original on September 1, 2020. Retrieved 6 September 2024.

globo.com

g1.globo.com

"Losartana: Anvisa determina recolhimento e interdição de lotes; veja o que fazer". g1 (in Portuguese). Grupo Globo. 23 June 2022. Retrieved 26 June 2022.

harvard.edu

ui.adsabs.harvard.edu

Pavel J, Benicky J, Murakami Y, Sanchez-Lemus E, Saavedra JM (December 2008). "Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo". Annals of the New York Academy of Sciences. 1148 (1): 360–6. Bibcode:2008NYASA1148..360P. doi:10.1196/annals.1410.006. PMC 2659765. PMID 19120129.

lww.com

journals.lww.com

Hubbert, Katherine; Clement, Ryan (April 2021). "Losartan: A Novel Treatment for Acute Skeletal Muscle Injury". JBJS Journal of Orthopaedics for Physician Assistants. 9 (2). doi:10.2106/JBJS.JOPA.20.00030. ISSN 2470-1122. S2CID 242846521. Retrieved 14 April 2022.

medscape.com

"Management of Hypertension in Chronic Heart Failure". Today on Medscape. Retrieved 2019-02-03.

nih.gov

pubmed.ncbi.nlm.nih.gov

"ARBs", Angiotensin II Receptor Antagonists, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID 31643954, retrieved 2020-03-21, The angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a family of agents that bind to and inhibit the angiotensin II type 1 receptor (AT₁) and thus inhibit the renin-angiotensin system and its cascade of effects in causing arteriolar contraction and sodium retention. While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide that causes a pressor response, the ARBs inhibit its peripheral action.
Hu, Yiyun (2023). "Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis". Journal of Clinical Hypertension (Greenwich, Conn.). 25 (8): 661–688. doi:10.1111/jch.14695. PMC 10423763. PMID 37417783.
Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P (November 1998). "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients". British Journal of Clinical Pharmacology. 46 (5): 467–71. doi:10.1046/j.1365-2125.1998.00811.x. PMC 1873694. PMID 9833600.
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (January 2003). "Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial". JAMA. 289 (1): 65–9. doi:10.1001/jama.289.1.65. PMID 12503978. S2CID 35939042.
Cernes R, Mashavi M, Zimlichman R (2011). "Differential clinical profile of candesartan compared to other angiotensin receptor blockers". Vascular Health and Risk Management. 7: 749–59. doi:10.2147/VHRM.S22591. PMC 3253768. PMID 22241949.
Gales BJ, Bailey EK, Reed AN, Gales MA (February 2010). "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines". The Annals of Pharmacotherapy. 44 (2): 360–6. doi:10.1345/aph.1M312. PMID 20086184. S2CID 207263658.
Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E (April 1998). "Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators". American Journal of Hypertension. 11 (4 Pt 1): 445–53. doi:10.1016/S0895-7061(97)00491-3. PMID 9607383.
Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B (January 2006). "Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population". Journal of Human Hypertension. 20 (1): 45–50. doi:10.1038/sj.jhh.1001941. PMID 16281062. S2CID 25534200.
Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M (2005). "Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia". Current Pharmaceutical Design. 11 (32): 4161–75. doi:10.2174/138161205774913309. PMID 16375738.
Pavel J, Benicky J, Murakami Y, Sanchez-Lemus E, Saavedra JM (December 2008). "Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo". Annals of the New York Academy of Sciences. 1148 (1): 360–6. Bibcode:2008NYASA1148..360P. doi:10.1196/annals.1410.006. PMC 2659765. PMID 19120129.
Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (January 2010). "Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis". BMJ. 340 (9): b5465. doi:10.1136/bmj.b5465. PMC 2806632. PMID 20068258.
Fuentes, Blanca (2010). "Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction". Journal of Hypertension. 28 (3): 575–581. doi:10.1097/HJH.0b013e3283350f50. PMID 20090554. S2CID 28972688.
Li EC, Heran BS, Wright JM (August 2014). "Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension". The Cochrane Database of Systematic Reviews. 2014 (8): CD009096. doi:10.1002/14651858.CD009096.pub2. PMC 6486121. PMID 25148386.
Strauss MH, Hall AS (August 2006). "Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox". Circulation. 114 (8): 838–54. doi:10.1161/CIRCULATIONAHA.105.594986. PMID 16923768.
Tsuyuki RT, McDonald MA (August 2006). "Angiotensin receptor blockers do not increase risk of myocardial infarction". Circulation. 114 (8): 855–60. doi:10.1161/CIRCULATIONAHA.105.594978. PMID 16923769.
Levy BI (September 2005). "How to explain the differences between renin angiotensin system modulators". American Journal of Hypertension. 18 (9 Pt 2): 134S – 141S. doi:10.1016/j.amjhyper.2005.05.005. PMID 16125050.
Lévy BI (January 2004). "Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system". Circulation. 109 (1): 8–13. doi:10.1161/01.CIR.0000096609.73772.C5. PMID 14707017.
Reudelhuber TL (December 2005). "The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous". Hypertension. 46 (6): 1261–2. doi:10.1161/01.HYP.0000193498.07087.83. PMID 16286568.
Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (July 2010). "Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials". The Lancet. Oncology. 11 (7): 627–36. doi:10.1016/S1470-2045(10)70106-6. PMC 4070221. PMID 20542468.
Rao GA, Mann JR, Shoaibi A, Pai SG, Bottai M, Sutton SS, et al. (August 2013). "Angiotensin receptor blockers: are they related to lung cancer?". Journal of Hypertension. 31 (8): 1669–75. doi:10.1097/HJH.0b013e3283621ea3. PMC 3879726. PMID 23822929.
Rao GA, Mann JR, Bottai M, Uemura H, Burch JB, Bennett CL, et al. (July 2013). "Angiotensin receptor blockers and risk of prostate cancer among United States veterans". Journal of Clinical Pharmacology. 53 (7): 773–8. doi:10.1002/jcph.98. PMC 3768141. PMID 23686462.
Zhao YT, Li PY, Zhang JQ, Wang L, Yi Z (May 2016). "Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials". Medicine. 95 (18): e3600. doi:10.1097/MD.0000000000003600. PMC 4863811. PMID 27149494.
Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA (October 1991). "Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis". Annals of Internal Medicine. 115 (7): 513–9. doi:10.7326/0003-4819-115-7-513. PMID 1883120.
Bakris GL, Weir MR (March 2000). "Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?". Archives of Internal Medicine. 160 (5): 685–93. doi:10.1001/archinte.160.5.685. PMID 10724055.
Remuzzi G, Ruggenenti P, Perico N (April 2002). "Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition". Annals of Internal Medicine. 136 (8): 604–15. doi:10.7326/0003-4819-136-8-200204160-00010. PMID 11955029. S2CID 24795760.
Sarafidis PA, Khosla N, Bakris GL (January 2007). "Antihypertensive therapy in the presence of proteinuria". American Journal of Kidney Diseases. 49 (1): 12–26. doi:10.1053/j.ajkd.2006.10.014. PMID 17185142. S2CID 18337587.
Weir MR (October 2002). "Progressive renal and cardiovascular disease: optimal treatment strategies". Kidney International. 62 (4): 1482–92. doi:10.1111/j.1523-1755.2002.kid591.x. PMID 12234333.
Miura, S; Karnik, SS; Saku, K (March 2011). "Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects". Journal of the Renin-Angiotensin-Aldosterone System. 12 (1): 1–7. doi:10.1177/1470320310370852. PMC 3891529. PMID 20603272.
Siragy HM (November 2002). "Angiotensin receptor blockers: how important is selectivity?". American Journal of Hypertension. 15 (11): 1006–14. doi:10.1016/s0895-7061(02)02280-x. PMID 12441224.
Fischer, Tracy L.; Pieper, John A.; Graff, Donald W.; Rodgers, Jo E.; Fischer, Jeffrey D.; Parnell, Kimberly J.; Goldstein, Joyce A.; Greenwood, Robert; Patterson, J. Herbert (September 2002). "Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers". Clinical Pharmacology and Therapeutics. 72 (3): 238–246. doi:10.1067/mcp.2002.127945. ISSN 0009-9236. PMID 12235444. S2CID 28606328.
Chi, Yong Ha; Lee, Howard; Paik, Soo Heui; Lee, Joo Han; Yoo, Byoung Wook; Kim, Ji Han; Tan, Hyun Kwang; Kim, Sang Lin (2011-10-01). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects". American Journal of Cardiovascular Drugs. 11 (5): 335–346. doi:10.2165/11593840-000000000-00000. ISSN 1179-187X. PMID 21910510. S2CID 207300735.
Burnier, M.; Brunner, H. R. (2000), "Angiotensin II receptor antagonists", Lancet, 355 (9204): 637–645, doi:10.1016/S0140-6736(99)10365-9, PMID 10696996, S2CID 18835715
Brousil, J. A.; Burke, J. M. (2003), "Olmesartan Medoxomil: An Angiotensin II-Receptor Blocker", Clinical Therapeutics, 25 (4): 1041–1055, doi:10.1016/S0149-2918(03)80066-8, PMID 12809956
Brunner, H. R. (2002), "The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview", Journal of Human Hypertension, 16 (2): 13–16, doi:10.1038/sj.jhh.1001391, PMID 11967728, S2CID 24382600, ProQuest 219966061
Zusman, R. M.; Jullien, V.; Lemetayer, P.; Jarnier, P.; Clementy, J. (1999), "Are There Differences Among Angiotensin Receptor Blockers?", American Journal of Hypertension, 12 (2 Pt 1): 231–235, doi:10.1016/S0895-7061(99)00116-8, PMID 10090354
Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. (March 2009). "Disruption of the Ang II type 1 receptor promotes longevity in mice". The Journal of Clinical Investigation. 119 (3): 524–30. doi:10.1172/JCI36703. PMC 2648681. PMID 19197138.
Cassis P, Conti S, Remuzzi G, Benigni A (January 2010). "Angiotensin receptors as determinants of life span". Pflügers Archiv. 459 (2): 325–32. doi:10.1007/s00424-009-0725-4. PMID 19763608. S2CID 24404339.
Salama, Zakaria A.; Sadek, Ahmed; Abdelhady, Ahmed M.; Darweesh, Samar Kamal; Morsy, Shereif Ahmed; Esmat, Gamal (June 2016). "Losartan may inhibit the progression of liver fibrosis in chronic HCV patients". Hepatobiliary Surgery and Nutrition. 5 (3): 249–255. doi:10.21037/hbsn.2016.02.06. ISSN 2304-3881. PMC 4876242. PMID 27275467.
Wang, J; Duan, L; Gao, Y; Zhou, S; Liu, Y; Wei, S; An, S; Liu, J; Tian, L; Wang, S (5 September 2018). "Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice". Molecular and Cellular Endocrinology. 472: 149–158. doi:10.1016/j.mce.2017.12.005. PMID 29233785. S2CID 6615686. Retrieved 14 April 2022.
Naito, T; Ma, LJ; Yang, H; Zuo, Y; Tang, Y; Han, JY; Kon, V; Fogo, AB (March 2010). "Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis". American Journal of Physiology. Renal Physiology. 298 (3): F683-91. doi:10.1152/ajprenal.00503.2009. PMC 2838584. PMID 20042458.

ncbi.nlm.nih.gov

"ARBs", Angiotensin II Receptor Antagonists, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID 31643954, retrieved 2020-03-21, The angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a family of agents that bind to and inhibit the angiotensin II type 1 receptor (AT₁) and thus inhibit the renin-angiotensin system and its cascade of effects in causing arteriolar contraction and sodium retention. While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide that causes a pressor response, the ARBs inhibit its peripheral action.
Hu, Yiyun (2023). "Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis". Journal of Clinical Hypertension (Greenwich, Conn.). 25 (8): 661–688. doi:10.1111/jch.14695. PMC 10423763. PMID 37417783.
Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P (November 1998). "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients". British Journal of Clinical Pharmacology. 46 (5): 467–71. doi:10.1046/j.1365-2125.1998.00811.x. PMC 1873694. PMID 9833600.
Cernes R, Mashavi M, Zimlichman R (2011). "Differential clinical profile of candesartan compared to other angiotensin receptor blockers". Vascular Health and Risk Management. 7: 749–59. doi:10.2147/VHRM.S22591. PMC 3253768. PMID 22241949.
Pavel J, Benicky J, Murakami Y, Sanchez-Lemus E, Saavedra JM (December 2008). "Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo". Annals of the New York Academy of Sciences. 1148 (1): 360–6. Bibcode:2008NYASA1148..360P. doi:10.1196/annals.1410.006. PMC 2659765. PMID 19120129.
Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (January 2010). "Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis". BMJ. 340 (9): b5465. doi:10.1136/bmj.b5465. PMC 2806632. PMID 20068258.
Li EC, Heran BS, Wright JM (August 2014). "Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension". The Cochrane Database of Systematic Reviews. 2014 (8): CD009096. doi:10.1002/14651858.CD009096.pub2. PMC 6486121. PMID 25148386.
Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (July 2010). "Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials". The Lancet. Oncology. 11 (7): 627–36. doi:10.1016/S1470-2045(10)70106-6. PMC 4070221. PMID 20542468.
Rao GA, Mann JR, Shoaibi A, Pai SG, Bottai M, Sutton SS, et al. (August 2013). "Angiotensin receptor blockers: are they related to lung cancer?". Journal of Hypertension. 31 (8): 1669–75. doi:10.1097/HJH.0b013e3283621ea3. PMC 3879726. PMID 23822929.
Rao GA, Mann JR, Bottai M, Uemura H, Burch JB, Bennett CL, et al. (July 2013). "Angiotensin receptor blockers and risk of prostate cancer among United States veterans". Journal of Clinical Pharmacology. 53 (7): 773–8. doi:10.1002/jcph.98. PMC 3768141. PMID 23686462.
Zhao YT, Li PY, Zhang JQ, Wang L, Yi Z (May 2016). "Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials". Medicine. 95 (18): e3600. doi:10.1097/MD.0000000000003600. PMC 4863811. PMID 27149494.
Miura, S; Karnik, SS; Saku, K (March 2011). "Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects". Journal of the Renin-Angiotensin-Aldosterone System. 12 (1): 1–7. doi:10.1177/1470320310370852. PMC 3891529. PMID 20603272.
Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. (March 2009). "Disruption of the Ang II type 1 receptor promotes longevity in mice". The Journal of Clinical Investigation. 119 (3): 524–30. doi:10.1172/JCI36703. PMC 2648681. PMID 19197138.
Salama, Zakaria A.; Sadek, Ahmed; Abdelhady, Ahmed M.; Darweesh, Samar Kamal; Morsy, Shereif Ahmed; Esmat, Gamal (June 2016). "Losartan may inhibit the progression of liver fibrosis in chronic HCV patients". Hepatobiliary Surgery and Nutrition. 5 (3): 249–255. doi:10.21037/hbsn.2016.02.06. ISSN 2304-3881. PMC 4876242. PMID 27275467.
Naito, T; Ma, LJ; Yang, H; Zuo, Y; Tang, Y; Han, JY; Kon, V; Fogo, AB (March 2010). "Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis". American Journal of Physiology. Renal Physiology. 298 (3): F683-91. doi:10.1152/ajprenal.00503.2009. PMC 2838584. PMID 20042458.

dailymed.nlm.nih.gov

"LOSARTAN- losartan potassium tablet, film coated". DailyMed. 2018-12-26. Retrieved 2019-02-06. 12.3 Pharmacokinetics/ Absorption: Following oral administration, the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3 to 4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC (area under the curve) of the metabolite is about 4 times as great as that of losartan. A meal slows absorption of losartan and decreases its Cmax but has only minor effects on losartan AUC or on the AUC of the metabolite (≈10% decrease). The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 mg and do not change over time.
"CANDESARTAN - candesartan tablet". DailyMed. 2017-06-27. Retrieved 2019-02-06.
"VALSARTAN - valsartan tablet". DailyMed. 2017-12-07. Retrieved 2019-02-06.
"IRBESARTAN - irbesartan tablet". DailyMed. 2018-09-04. Retrieved 2019-02-06.
"TELMISARTAN - telmisartan tablet". DailyMed. 2018-11-01. Retrieved 2019-02-06.
"EPROSARTAN MESYLATE- eprosartan mesylate tablet, film coated". DailyMed. 2014-12-05. Retrieved 2019-02-06.
"OLMESARTAN MEDOXOMIL - olmesartan medoxomil tablet, film coated". DailyMed. 2017-05-04. Retrieved 2019-02-06.
"EDARBI- azilsartan kamedoxomil tablet". DailyMed. 2018-01-25. Retrieved 2019-02-06.

pharmacytimes.com

Tom Hostetter, M. D. (June 2004). "ACE Inhibitors and ARBs in Patients with Kidney Disease". Pharmacy Times. Retrieved 2019-02-05.

proquest.com

Brunner, H. R. (2002), "The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview", Journal of Human Hypertension, 16 (2): 13–16, doi:10.1038/sj.jhh.1001391, PMID 11967728, S2CID 24382600, ProQuest 219966061

quickcompany.in

"Process For The Preparation Of Carcinogenic Azido Impurities Free Losartan And Salts Thereof". 5 April 2022. Retrieved 26 June 2022.

semanticscholar.org

api.semanticscholar.org

Mirabito Colafella, Katrina M.; Uijl, Estrellita; Jan Danser, A.H. (2019). "Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches". Encyclopedia of Endocrine Diseases. Elsevier. pp. 523–530. doi:10.1016/b978-0-12-801238-3.65341-2. ISBN 978-0-12-812200-6. S2CID 86384280.
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (January 2003). "Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial". JAMA. 289 (1): 65–9. doi:10.1001/jama.289.1.65. PMID 12503978. S2CID 35939042.
Gales BJ, Bailey EK, Reed AN, Gales MA (February 2010). "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines". The Annals of Pharmacotherapy. 44 (2): 360–6. doi:10.1345/aph.1M312. PMID 20086184. S2CID 207263658.
Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B (January 2006). "Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population". Journal of Human Hypertension. 20 (1): 45–50. doi:10.1038/sj.jhh.1001941. PMID 16281062. S2CID 25534200.
Fuentes, Blanca (2010). "Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction". Journal of Hypertension. 28 (3): 575–581. doi:10.1097/HJH.0b013e3283350f50. PMID 20090554. S2CID 28972688.
Tucker, Bryan M.; Perazella, Mark A. (2019). "Medications: 3. What are the major adverse effects on the kidney of ACE inhibitors and ARBs?". Nephrology Secrets. Elsevier. pp. 78–83. doi:10.1016/b978-0-323-47871-7.00019-8. ISBN 978-0-323-47871-7. S2CID 239423283. due to inhibition of angiotensin II production by ACE inhibitors or competitive antagonism of the angiotensin II receptor by ARBs... results in loss of angiotensin II–induced efferent arteriolar tone, leading to a drop in glomerular filtration fraction and GFR. The efferent arteriolal vasodilation reduces intraglomerular hypertension (and pressure-related injury) and maintains perfusion (and oxygenation) of the peritubular capillaries.
Remuzzi G, Ruggenenti P, Perico N (April 2002). "Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition". Annals of Internal Medicine. 136 (8): 604–15. doi:10.7326/0003-4819-136-8-200204160-00010. PMID 11955029. S2CID 24795760.
Sarafidis PA, Khosla N, Bakris GL (January 2007). "Antihypertensive therapy in the presence of proteinuria". American Journal of Kidney Diseases. 49 (1): 12–26. doi:10.1053/j.ajkd.2006.10.014. PMID 17185142. S2CID 18337587.
Fischer, Tracy L.; Pieper, John A.; Graff, Donald W.; Rodgers, Jo E.; Fischer, Jeffrey D.; Parnell, Kimberly J.; Goldstein, Joyce A.; Greenwood, Robert; Patterson, J. Herbert (September 2002). "Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers". Clinical Pharmacology and Therapeutics. 72 (3): 238–246. doi:10.1067/mcp.2002.127945. ISSN 0009-9236. PMID 12235444. S2CID 28606328.
Chi, Yong Ha; Lee, Howard; Paik, Soo Heui; Lee, Joo Han; Yoo, Byoung Wook; Kim, Ji Han; Tan, Hyun Kwang; Kim, Sang Lin (2011-10-01). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects". American Journal of Cardiovascular Drugs. 11 (5): 335–346. doi:10.2165/11593840-000000000-00000. ISSN 1179-187X. PMID 21910510. S2CID 207300735.
Burnier, M.; Brunner, H. R. (2000), "Angiotensin II receptor antagonists", Lancet, 355 (9204): 637–645, doi:10.1016/S0140-6736(99)10365-9, PMID 10696996, S2CID 18835715
Brunner, H. R. (2002), "The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview", Journal of Human Hypertension, 16 (2): 13–16, doi:10.1038/sj.jhh.1001391, PMID 11967728, S2CID 24382600, ProQuest 219966061
Cassis P, Conti S, Remuzzi G, Benigni A (January 2010). "Angiotensin receptors as determinants of life span". Pflügers Archiv. 459 (2): 325–32. doi:10.1007/s00424-009-0725-4. PMID 19763608. S2CID 24404339.
Hubbert, Katherine; Clement, Ryan (April 2021). "Losartan: A Novel Treatment for Acute Skeletal Muscle Injury". JBJS Journal of Orthopaedics for Physician Assistants. 9 (2). doi:10.2106/JBJS.JOPA.20.00030. ISSN 2470-1122. S2CID 242846521. Retrieved 14 April 2022.
Wang, J; Duan, L; Gao, Y; Zhou, S; Liu, Y; Wei, S; An, S; Liu, J; Tian, L; Wang, S (5 September 2018). "Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice". Molecular and Cellular Endocrinology. 472: 149–158. doi:10.1016/j.mce.2017.12.005. PMID 29233785. S2CID 6615686. Retrieved 14 April 2022.

swissmedic.ch

Swissmedic (1 July 2021). "Monitoring of sartan medicines stepped up: traces of a new foreign substance detected". Retrieved 26 June 2022.

tga.gov.au

Therapeutic Goods Administration (TGA) (20 August 2021). "Azide impurity in 'sartan' blood pressure medicines". Retrieved 26 June 2022.

uptodate.com

"Choice of drug therapy in primary (essential) hypertension". UpToDate. Retrieved 2019-02-03.

web.archive.org

"Blood Pressure : Angiotensin receptor blockers (ARBs)". blood pressure medication. Archived from the original on 2012-12-14. Retrieved 2020-03-21.
"Angiotensin FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs – Angiotensin Receptor Blockers (ARBs)". Food and Drug Administration (FDA). 2 June 2011. Archived from the original on 8 December 2011.
Burton, Thomas M. (31 May 2013). "Dispute Flares Inside FDA Over Safety of Popular Blood-Pressure Drugs". The Wall Street Journal. Archived from the original on 15 February 2018. Retrieved 1 May 2018.
"Saprisartan". drugbank.ca. Archived from the original on 28 September 2016. Retrieved 1 May 2018.
"FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)". Food and Drug Administration (FDA). 20 August 2018. Archived from the original on April 28, 2019. Retrieved 17 September 2019.
"Statement on the agency's ongoing efforts to resolve safety issue with ARB medications". Food and Drug Administration (FDA). 28 August 2019. Archived from the original on August 28, 2019. Retrieved 17 September 2019.
"FDA's Assessment of Currently Marketed ARB Drug Products". Food and Drug Administration (FDA). 4 April 2019. Archived from the original on 30 December 2019. Retrieved 17 September 2019.
"Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP". U.S. Food and Drug Administration. 23 September 2019. Archived from the original on September 24, 2019. Retrieved 24 September 2019.
"General Advice ARB". Food and Drug Administration (FDA). Archived from the original (PDF) on November 12, 2019. Retrieved 17 September 2019. This article incorporates text from this source, which is in the public domain.
"M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk". Food and Drug Administration (FDA). 30 August 2018. Archived from the original (PDF) on August 28, 2019. Retrieved 17 September 2019.
"Control of Nitrosamine Impurities in Human Drugs". U.S. Food and Drug Administration. 24 February 2021. Archived from the original on September 1, 2020. Retrieved 6 September 2024.

worldcat.org

search.worldcat.org

Fischer, Tracy L.; Pieper, John A.; Graff, Donald W.; Rodgers, Jo E.; Fischer, Jeffrey D.; Parnell, Kimberly J.; Goldstein, Joyce A.; Greenwood, Robert; Patterson, J. Herbert (September 2002). "Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers". Clinical Pharmacology and Therapeutics. 72 (3): 238–246. doi:10.1067/mcp.2002.127945. ISSN 0009-9236. PMID 12235444. S2CID 28606328.
Chi, Yong Ha; Lee, Howard; Paik, Soo Heui; Lee, Joo Han; Yoo, Byoung Wook; Kim, Ji Han; Tan, Hyun Kwang; Kim, Sang Lin (2011-10-01). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects". American Journal of Cardiovascular Drugs. 11 (5): 335–346. doi:10.2165/11593840-000000000-00000. ISSN 1179-187X. PMID 21910510. S2CID 207300735.
Hubbert, Katherine; Clement, Ryan (April 2021). "Losartan: A Novel Treatment for Acute Skeletal Muscle Injury". JBJS Journal of Orthopaedics for Physician Assistants. 9 (2). doi:10.2106/JBJS.JOPA.20.00030. ISSN 2470-1122. S2CID 242846521. Retrieved 14 April 2022.
Salama, Zakaria A.; Sadek, Ahmed; Abdelhady, Ahmed M.; Darweesh, Samar Kamal; Morsy, Shereif Ahmed; Esmat, Gamal (June 2016). "Losartan may inhibit the progression of liver fibrosis in chronic HCV patients". Hepatobiliary Surgery and Nutrition. 5 (3): 249–255. doi:10.21037/hbsn.2016.02.06. ISSN 2304-3881. PMC 4876242. PMID 27275467.
Weinberg MS, Weinberg AJ, Cord RB, Martin H (1 May 2003). "P-609: Regression of dilated aortic roots using supramaximal and usual doses of angiotensin receptor blockers". American Journal of Hypertension. 16 (S1): 259A. doi:10.1016/S0895-7061(03)00782-9. ISSN 0895-7061. In conclusion, we demonstrated regression of DAR using ARBs at moderate and supramaximal doses. Intensive ARB therapy offers a promise to reduce the natural progression of disease in patients with DARs.

wsj.com

Burton, Thomas M. (31 May 2013). "Dispute Flares Inside FDA Over Safety of Popular Blood-Pressure Drugs". The Wall Street Journal. Archived from the original on 15 February 2018. Retrieved 1 May 2018.